TRIM9 and neoplasm: Subsequently, to further validate the role of TRIM9 in tumor recurrence, we obtained 22 clinical bladder tumor tissues, in which patients were divided into recurrent and non-recurrent groups according to 5-years follow-up visit (Fig. S1A).